EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study

Javier P Gisbert iD, Stefan Schreiber, Corey A Siegel, Fernando Magro iD, Anna Jus, Chiara Whichello, Christine Michaels-Igbokwe, Sebastian Heidenreich, Alessandra Oortwijn, Séverine Vermeire iD

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izae162 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Javier P Gisbert und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de M…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Patient Preference, Pyridines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To help navigate the complex treatment landscape of ulcerative colitis (UC), we quantified the benefit-risk trade-offs that patients were willing to make when choosing treatment.

Methods

Patients completed an online discrete choice experiment. Eligible patients had a UC diagnosis for ≥6 months, were aged ≥18 years, and resided in France, Germany, Italy, Spain, or the UK. Patients chose between 2 hypothetical treatments set up to ensure trade-offs were made. Clinical trial data, literature review, and patient interviews identified treatment attributes. Relative attribute importance (RAI) scores and maximum acceptable risks were generated. A patient-centric benefit-risk assessment of 200 mg of filgotinib was conducted as an example to show how measured trade-offs can be used.

Results

Overall, 631 patients participated; patients had a mean age of 42.2 years and were predominantly male (75.3%). Achieving and maintaining clinical remission was the most important factor for patients (RAI 32.4%); to achieve this, patients were willing to accept slightly higher risks of blood clots, serious infections, and malignancies compared with lower risk treatment profiles. Patients also valued the convenience of oral treatments, avoiding steroids, and the ability to attend school/work. The patient-centric benefit-risk assessment suggested patients are significantly more likely to prefer Janus kinase 1 preferential inhibitor filgotinib over placebo.

Conclusions

Achieving clinical remission was the highest treatment priority for patients. To attain this, patients were willing to accept some slightly higher risk treatment profiles. Patient choices in the benefit-risk assessment suggested patients were significantly more likely to prefer filgotinib over placebo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativePatient PreferencePyridinesHumansMaleFemaleAdultMiddle AgedRisk AssessmentChoice BehaviorYoung AdultTriazolesPrognosisAged

Stichwörter der Autor:innen

benefit-risk assessmentfilgotinibulcerative colitis

Substanzen

GLPG0634TriazolesPyridines

Autor:innen und Institutionen

  • Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Madrid, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Carlos III Health Institute, Madrid, Spain.
  • Department of Internal Medicine I, Kiel University, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Inflammatory Bowel Disease Center, Section of Gastroenterology & Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
  • The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
  • CINTESIS@RISE, Faculty of Medicine, University of Porto, Porto, Portugal.

ORCID-Profile: Javier P Gisbert, Fernando Magro, Séverine Vermeire

Förderung

  • Gilead Sciences

Zitieren

APA

Gisbert, J. P., Schreiber, S., Siegel, C. A., Magro, F., Jus, A., Whichello, C., Michaels-Igbokwe, C., Heidenreich, S., Oortwijn, A., & Vermeire, S. (2025). Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae162

Vancouver

Gisbert JP, Schreiber S, Siegel CA, Magro F, Jus A, Whichello C, et al. Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae162

BibTeX
@article{Gisbert2025,
  author = {Gisbert, Javier P and Schreiber, Stefan and Siegel, Corey A and Magro, Fernando and Jus, Anna and Whichello, Chiara and Michaels-Igbokwe, Christine and Heidenreich, Sebastian and Oortwijn, Alessandra and Vermeire, Séverine},
  title = {Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izae162}
}
Kostenlos starten →